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Question: Is there a dose-response effect of exercise on inﬂammation, fatigue and activity in cancer
survivors? Design: Systematic review with meta-regression analysis of randomised trials. Participants:
Adults diagnosed with cancer, regardless of speciﬁc diagnosis or treatment. Intervention: Exercise
interventions including aerobic and/or resistance as a key component.Outcomemeasures: The primary
outcome measures were markers of inﬂammation (including C-reactive protein and interleukins) and
variousmeasures of fatigue. The secondary outcomeswere:measures of activity, as deﬁned by theWorld
Health Organization’s International Classiﬁcation of Functioning, Disability and Health, including
activities of daily living and measures of functional mobility (eg, 6-minute walk test, timed sit-to-stand
and stair-climb tests). Risk of bias was evaluated using the PEDro scale, and overall quality of evidence
was assessed using the Grades of Research, Assessment, Development and Evaluation (GRADE)
approach. Results: Forty-two trials involving 3816 participants were included. There was very low-
quality to moderate-quality evidence that exercise results in signiﬁcant reductions in fatigue (SMD 0.32,
95% CI 0.13 to 0.52) and increased walking endurance (SMD 0.77, 95% CI 0.26 to 1.28). A signiﬁcant
negative association was found between aerobic exercise intensity and fatigue reduction. A peak effect
was found for moderate-intensity aerobic exercise for improving walking endurance. No dose-response
relationship was found between exercise and markers of inﬂammation or exercise duration and
outcomes. Rates of adherence were typically high and few adverse events were reported. Conclusions:
Exercise is safe, reduces fatigue and increases endurance in cancer survivors. The results support the
recommendation of prescribing moderate-intensity aerobic exercise to reduce fatigue and improve
activity in people with cancer. Review registration: PROSPERO CRD42015019164. [Dennett AM, Peiris
CL, Shields N, Prendergast LA, Taylor NF (2016) Moderate-intensity exercise reduces fatigue and
improves mobility in cancer survivors: a systematic review and meta-regression. Journal of
Physiotherapy 62: 68–82]
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nc-nd/4.0/).Introduction
Cancer is a leading cause of burden of disease globally1 and is
responsible for approximately three in 10 deaths.2 However, with
improved screening and advancing treatment options, survival
rates are improving. As a result, cancer is now recognised as a
chronic disease.3,4 While treatment may improve survival, the
side-effects on physical and psychological function often reduce
quality of life. There is an increasing need for rehabilitation to
address these issues.
Exercise is an effective treatment for many chronic diseases.
Recent systematic reviews have demonstrated that exercise used
as part of cancer care reduces cancer-related fatigue and improves
cardiovascular function, strength and quality of life.5–9 There is
also emerging evidence that exercise can reduce recurrence and
mortality in some cancer populations.10–16
Despite these beneﬁts of exercise, there is a lack of evidence on
the safety and efﬁcacy of exercise in relation to dose.6,17 The idealhttp://dx.doi.org/10.1016/j.jphys.2016.02.012
1836-9553/Crown Copyright  2016 Published by Elsevier B.V. on behalf of Australian
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).mode and intensity of exercise for people with cancer is unclear,
and exercise guidelines are based largely on expert clinical opinion
and adaptations of guidelines for healthy people. Current
recommendations suggest that cancer survivors complete at least
150 minutes of moderate-intensity physical activity per week.6
However, these recommendations may not recognise the speciﬁc
health needs of cancer survivors. Recent reviews have reported a
low number of adverse events in relation to exercise trials,6,7,18–20
suggesting that exercise is generally safe for cancer survivors.
However, in these reviews, there has been variable reporting of the
dose of prescribed exercise.
The association between inﬂammation and cancer is well
documented.21–23 Chronic inﬂammation plays a role in the
pathogenesis of insulin resistance and tumour growth, and has
been linked to cancer risk and mortality.23–26 Inﬂammatory
cytokines have also been implicated in the development of
cancer-related fatigue.27–29 Exercise plays a role in mediating
the effects of chronic inﬂammation, reducing inﬂammatoryPhysiotherapy Association. This is an open access article under the CC BY-NC-ND
Box 1. Inclusion criteria.
Design
 Randomised trial
 Published in English
Participants
 Adults with cancer
Intervention
 Exercise intervention with aerobic or resistance exercise as a
key component
 Sufficient reporting of dose (ie, the intensity or durationmust
be reported). For combined modalities, the intensity or total
duration for both components must be specified.
Outcome measures
Must report at least one measure of fatigue or inflammation
Comparisons
 Exercise versus control
 Exercise plus usual care versus usual care only
One exercise dose compared to another (eg, high versus low
intensity)
Research 69markers such as C-reactive protein (CRP), tumour necrosis factor-
alpha, and various types of interleukin (IL), including IL6, in people
with and without cancer.30–32 Furthermore, the protective effects
of exercise have been attributed to the creation of an anti-
inﬂammatory environment through increasing anti-inﬂammatory
cytokines such as ILRa and IL10 in healthy people.26,33,34 The
relationship between exercise dose and inﬂammatory markers in
people with cancer needs to be considered because strenuous
exercise can induce pro-inﬂammatory cytokines in healthy
people.35 Therefore, it is important to know how much exercise
can be safely tolerated in this immune-compromised population of
people with cancer.
Cancer-related fatigue affects 80 to 100% of patients.36 Fatigue
is a complex multi-dimensional construct related to reduced
physical function and reduced health-related quality of life.27,37
Recent reviews have concluded that exercise reduces cancer-
related fatigue,19,38–40 but the optimal dose to achieve this has not
been established. It has been suggested that patients undergoing
treatmentmay need to exercise at a lower intensity or for a shorter
duration than those who have completed primary treatment.41
However, others have suggested that higher-intensity exercise
may be better.42,43 For example, Brown et al40 found that
moderate-intensity resistance exercise may be more effective
than low-intensity exercise for reducing cancer-related fatigue.
The most effective duration and intensity of exercise remain
unclear.
Therefore, the research questions that we sought to answer
with this systematic review were:1. Is there a dose-response effect of exercise on inﬂammation and
fatigue in adult cancer survivors?2. Is there a dose-response effect of exercise for improving
functional activity in this population?
Method
This systematic review was reported in accordance with
PRISMA guidelines.44,45
Search strategy
The Medline, EMBASE and CINAHL databases were searched
from the earliest records to April 2015. PubMed was also searched
from 2010 for more recent publications. The search strategy was
based around synonyms and MeSH subject headings of the key
concepts of exercise and cancer combined with the primary
outcomes of fatigue and inﬂammation. These terms were combined
with relevant ﬁlters to identify randomised, controlled trials.46 The
detailed search strategy is presented in Appendix 1 (see
eAddenda). The database searches were supplemented by citation
tracking of included articles using Google Scholar and checking the
reference lists of included studies.
Eligibility criteria
The eligibility of papers identiﬁed by the searches was assessed
by two reviewers who independently considered information from
the titles and abstracts against predetermined eligibility criteria
(Box 1). Disagreements were resolved by discussion, with a third
reviewer consulted when necessary. Where eligibility was unclear
from the title and abstract, the full-text version was obtained and
examined by both reviewers.
To be included, studies had to be randomised, controlled trials
that: examined the effect of exercise in adults who had been
diagnosed with cancer, reported at least one of the primary
outcomes (fatigue or inﬂammation) andwere published in English.
The exercise intervention had to meet the deﬁnition ‘physical
activity that is planned, structured and repetitive and has a ﬁnal or
intermediate objective of the improvement or maintenance of
physical ﬁtness’47 with aerobic or resistance training as a keycomponent, because thesemodes of exercise are expected to result
in signiﬁcant physiological changes that may affect inﬂammation
and fatigue, and are quantiﬁable. Furthermore, the intensity (eg,
percentage of maximum heart rate, repetition maximum, etc) or
duration of completed exercise needed to be reported. For studies
using a combined exercise intervention (ie, aerobic and resistance
training), the intensity or total duration for both components must
have been speciﬁed. Studies were excluded if only a single bout of
exercise was used or if it was combined with a co-intervention
such as diet or education.
Quality assessment
The studies were assessed by two reviewers, who indepen-
dently rated the 11 criteria on the PEDro scale as yes or no. One
criterion relates to external validity; the remaining 10 criteria
contribute 1 point each, if met, to give a score out of 10. The PEDro
score is a valid measure of internal validity and completeness of
reporting. It has undergone Rasch analysis and hasmoderate levels
of inter-rater reliability (ICC 0.68, 95% CI 0.57 to 0.76).48,49 Trials
scoring < 6 were deemed to be of low quality.50
Synthesis of results
A standardisedmean difference (SMD) was calculated for each
outcome from post-intervention means and SDs to compare the
control and treatment groups and to account for different scales
of measurement between studies. Where only change scores
were reported, the post-intervention mean was estimated in
reference to the baselinemean and the SD based on baseline data.
If only a range was given, the SD was calculated.51 Authors were
contacted if there was insufﬁcient published data for analysis.
Data from outcome measures were classiﬁed into three catego-
ries to address the primary and secondary aims of the review:
inﬂammation, fatigue and activity. Activity was deﬁned accord-
ing to the World Health Organization International Classiﬁcation
of Functioning as ‘the execution of a task or action by an
individual’, which included measures of activities of daily living
and functional mobility.52
Meta-analysis was completed using the R statistics package
‘metafor’53 to provide evidence of the pooled effect size of the
exercise intervention. Data were combined if clinically homoge-
nous for more than two trials. Random effects models and a
restricted maximum likelihood estimator for the random effect
variance parameter were used.54 A meta-analysis of the ratio of
sample variances55 provided evidence of unequal variances
[(Figure_1)TD$FIG]
Titles and abstracts screened (n = 683) 
Full-text articles assessed for eligibility (n = 82) 
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Excluded after evaluation of full text (n = 33) 
• not a randomised trial (n = 10) 
• co-intervention (n = 8) 
• insufficient reporting of dose (n = 5) 
• no measure of fatigue or inflammation (n = 3) 
• inadequate control (n = 3) 
• issues with group randomisation or analysis 
(n = 3) 
• participants receiving end-of-life care (n = 1) 
Papers found via search 
of databases (n = 874) 
Papers found via reference 
lists or citation tracking (n = 6) 
Records after duplicates removed (n = 683) 
Trials included in review (n = 42) 
Trials included in meta-analysis (n = 34) 
Inadequate data for meta-analysis (n = 8) 
Duplicate trial data (n = 7) 
Trials included in meta-regression (n = 31) 
Inadequate data for meta-regression of 
inflammation (n = 3) 
Figure 1. Flow of trials through the review.
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D56 was employed where the difference in means was standar-
dised using the control-group sample SD. Subgroup analyses were
completed to determine the effect of tumour stream, treatment
status and exercise modality. The Grades of Research, Assessment,
Development and Evaluation (GRADE) approach was applied to
each meta-analysis to evaluate the evidence across trials.57 The
approach involved downgrading the evaluation based on these
predetermined criteria: the PEDro scorewas< 6 for themajority of
trials used in the meta-analysis; there was greater than low levels
of statistical heterogeneity between trials (I2 > 25%); there were
large conﬁdence intervals (ie, > 0.8 SMD); and if there was
asymmetry of a funnel plot when more than 10 trials were
included in the meta-analysis, demonstrating evidence of publi-
cation bias.
Meta-regression analysis assessed the pooled dose-response
relationship between exercise dose and outcomes. To standardise
dose for analysis, duration of exercise per week and intensity were
evaluated separately, with intensity quantiﬁed as maximum
oxygen consumption (VO2max) or a percentage of one repetition
maximum (1RM). Meta-regression models were ﬁtted to both
factor and numeric variables to obtain subgroup estimates (for the
factor variables) and estimated increases in effect sizes for one-
unit changes of numeric covariates. Analysing exercise dose by
volume in metabolic equivalents (METs)/minute/week was con-
sidered; however, there were inadequate data. Exercise intensity
was categorised as low (< 40% VO2max, < 60% 1RM), moderate
(40 to 60% VO2max, 60 to 80% 1RM) or vigorous/high (> 60%VO2max,
> 80% 1RM).58,59 Where outcome data could not be included in the
meta-analysis or meta-regression, results were summarised
descriptively.
Results
Study selection
The electronic database search resulted in a yield of 874 articles,
which was reduced to 677 after the duplicates were removed.
Additional articles were identiﬁed through citation tracking (n = 2)
and reference list scanning (n = 4). Eighty-two articles were
obtained in full text and further assessment reduced the yield to
49 articles. There was good inter-rater agreement about eligibility
based on title and abstract (k = 0.695) and full texts (k = 0.691).
Fourteen articles reported data from seven trials; therefore,
42 trials were included for review (Figure 1).
Quality
The mean score of the included trials was 5.7 (SD 1.4) on the
PEDro scale (Table 1). Inter-rater agreement on quality criteria was
very good (k = 0.848). Three trials60–62 scored 8 on the PEDro scale,
which was the highest possible score given the nature of the
intervention that was studied, where it would be unfeasible to
blind clinicians or participants. Less than half of the trials had
blinding of assessment and concealed allocation.
Study characteristics
Participants
Data from 3816 participants were included. The majority of
participants were female (70%), with a mean age of 55 years (SD 9)
and a mean body mass index of 27 kg/m2. Solid tumours were
investigated in 34 trials (81%), haematological cancers were
investigated in four trials,63–66 with an additional four trials
investigating a combination of solid and haematological can-
cers.67–70 Breast cancerwas themost frequently reported (27 trials,
64%),30,60–62,68–94 followed by prostate cancer (14 trials,
24%).85,88,90,92,95–104 Interventions were commonly completed
during the treatment phase (30 trials, 71%), with 12 trials
completed in the post-treatment phase (Table 2).Intervention
Trials included aerobic exercise (19 trials),30,60,61,63,68,70,72,78,
80–84,86,87,89,91,92,101,104–106 resistance exercise (ﬁve trials),68,88,93,
98,99,102,107 a combination of aerobic and resistance exercise
(14 trials)62,64–67,69,71,73,74,79,85,90,95–97,100 and four trials75–77,94,103
compared one exercise modality to another (eg, aerobic versus
resistance exercise). The interventionswereusually completed inan
outpatient rehabilitation or ﬁtness centre (20 trials),30,60,61,68,69,
71–80,82,95,97–103,105 athome (13 trials)64,70,81,84–87,90–92,94,96,104,106or
a combination of home and centre-based exercise (ﬁve trials).62,83,
88,89,93 The remaining four trials were completedwhile participants
were inpatients.63,65–67 Of the 23 trials that reported using
supervision, 11 were supervised by an exercise specialist,30,60,62,66,
71,75,85,90,95,97,98,100,103,105 six by physiotherapists,68,69,74,80,88,89,96
four by a ﬁtness trainer,70,83,93,99,102 one by a kinesiotherapist and
physician,101 and one by a trained research assistant.63
The duration of the intervention ranged from 15 days65 to
1 year,89,93 with most trials of at least 12 weeks duration. The
exercise sessions were 10 to 90 minutes long, and completed two
to three times per week. The average amount of exercise
completed each week across the trials was 104 minutes. The
intensity of the interventions varied from moderate, between 60%
of maximal heart rate86,91 for aerobic exercise and 60% of 1RM for
Table 1
PEDro scores of the included studies.
Study Random
allocation
Allocation
concealed
Groups
similar at
baseline
Participant
blinding
Therapist
blinding
Assessor
binding
< 15%
dropout
Intention
to treat
Between-group
comparisons
reported
Point
measures and
variability
reported
Total
(0 to 10)
Battaglini 200871 Y N N N N N N N Y Y 3
Baumann 201067 Y N Y N N N N Y Y Y 5
Broderick 201368 a Y N Y N N Y Y N Y Y 6
Guinan 201380 Y N Y N N Y N Y Y Y 6
Buffart 201495 a Y N Y N N N Y N Y Y 5
Galvao 2010100 Y Y Y N N N Y Y Y Y 7
Burnham 200272 Y N Y N N N Y N Y Y 5
Campbell 200573 Y N Y N N N Y N Y Y 5
Cantarero-Villanueva 201374 Y Y Y N N Y Y N Y Y 7
Chang 200863 Y N N Y N N Y Y N Y 5
Cheville 201396 Y Y Y N N N N Y Y Y 6
Christensen 2014107 Y N Y N N Y Y N Y Y 6
Coleman 201264 Y N Y N N N Y N Y Y 5
Cormie 201398 Y Y Y N N N N Y Y Y 6
Cormie 201597 Y Y Y N N N Y Y Y Y 7
Courneya 200499 a Y N Y N N N Y N Y Y 5
Segal 2003102 Y Y Y N N Y N Y Y Y 7
Courneya 200776 a Y Y Y N N N Y Y Y Y 7
Courneya 200777 Y N Y N N N Y Y Y Y 6
Courneya 2009105 Y Y Y N N N Y Y Y Y 7
Courneya 201375 Y Y Y N N N Y Y Y Y 7
Daley 200778 Y Y Y N N N Y Y Y Y 7
Fairey 200530 a Y Y Y N N Y Y Y Y Y 8
Fairey 200560 Y N Y N N Y Y Y Y Y 7
Gomez 201179 Y N Y N N N N N Y Y 4
Headley 200481 Y N Y N N N N N Y Y 4
Hornsby 201461 a Y Y Y N N Y Y Y Y Y 8
Jones 201382 Y N Y N N N Y Y Y Y 6
Jones 201383 Y N Y N N Y Y Y Y Y 7
Mock 200584 Y Y Y N N N Y Y Y Y 7
Monga 2007101 Y N N N N N N N Y Y 3
Mustian 200985 a Y Y N N N N Y Y Y Y 6
Sprod 201090 Y N Y N N N Y Y Y Y 6
Mutrie 200762 Y Y Y N N Y Y Y Y Y 8
Naraphong 201586 Y Y Y N N Y N Y Y Y 7
Oechsle 201465 Y N Y N N N Y N Y N 4
Oldervoll 201169 Y N Y N N N N Y Y Y 5
Payne 200887 Y N N N N N Y N Y N 3
Rief 201488 Y Y N N N N N N Y Y 4
Saarto 201289 Y Y Y N N N Y Y Y Y 7
Segal 2009103 Y Y Y N N N Y Y Y Y 7
Thorsen 200570 Y Y N N N N N Y Y Y 5
Wang 201191 Y N N N N N Y N Y Y 4
Wenzel 201392 Y N Y N N N Y Y Y Y 6
Winters-Stone 201293 Y Y Y N N Y N Y Y Y 7
Windsor 2004104 Y Y Y N N N Y N Y Y 5
Wiskemann 201166 Y N Y N N N N N Y Y 4
Yeo 2012106 Y Y Y N N N Y N Y N 5
Yuen 200794 Y N Y N N N N N N Y 3
N=no, Y=yes
a reports data on some or all of the same participants as the study below.
Research 71resistance exercise,65 to high intensity, 100% of peak workload as
interval training for aerobic exercise61,82,105 and 85% of 1RM for
resistance exercise97 (Table 3). No trials implemented low-
intensity exercise.Adverse events and adherence
Theexercise interventionsappeared tobesafe andwell tolerated.
Of the 22 trials9,55,60,61,65,67–69,72–75,77–79,84,88,91,96–98,103,105
reporting an adverse event, 19 of the 1888 exercise participants
Table 2
Summary of trial characteristics.
Study N Gender
(% F)
Age (y)
mean (SD)
Tumour stream Time period relative to
treatment and type(s) of
therapy
Outcome measure
Inﬂammation Fatigue Activity
Battaglini 200871 20 100 57 (17) Breast On: chemotherapy  surgery
 radiotherapy
 Revised PFS
Baumann 201067 64 45 45 (12) Lymphoma, leukaemia,
solid tumourb
On: HSCT 100%  EORTC
QLQ-C30
Broderick 201368 a 43 86 51 (9) Breast, colon, lymphoma,
oesophageal,
gynaecological
Post: time post-
chemotherapy 4 (S SD 1) mth;
surgery 93%, chemotherapy
100%, radiotherapy 72%
 FACIT-F
Guinan 201380 26 100 48 (9) Breast Post: time post-
chemotherapy 4 (SD 1) mth;
chemotherapy 100%
radiotherapy 32.4%, hormone
therapy 76.9%, surgery 100%
 CRP
Buffart 201495 a
Galvao 2010100
57 0 70 (3) Prostate On: ADT + previous
radiotherapy 39%,
chemotherapy 25%
 CRP  EORTC
QLQ-C30
 400-m walk
 6-m walk
 Timed STS
Burnham 200272 18 83 54 (9) Breast, colon Post: average 10 mth; surgery
61%, chemotherapy 78%,
radiotherapy 56%
 LASA
Campbell 200573 22 100 48 (8) Breast On: chemotherapy 73%,
radiotherapy 73%,
combination 45%
 Revised PFS  12-MWT
Cantarero-
Villanueva 201374
61 100 48 (15) Breast Post: surgery 100%,
chemotherapy 97%,
radiotherapy 90%, hormone
100%
 PFS  Timed
STS x 10
Chang 200863 22 45 51 (55) Acute myelogenous
leukaemia
On: chemotherapy 100%  BFI  12-MWT
Cheville 201396 66 47 65 (18) Lung, colon On:
chemotherapy radiotherapy
 FACT-F  AM-PAC SF
Christensen 2014107 30 0 35 (11) Germ cell On: average 158 days, surgery
100%, chemotherapy 100%
 IL: 1b, 2, 6, 8,
10, 12
 EORTC
QLQ-C30
Coleman 201264 187 42 56 (4) Multiple myeloma On: chemotherapy, hormone
therapy, stem cell treatment
 FACT-F  6-MWT
Cormie 201398 20 0 72 (13) Prostate Post: AST 100%, radiation 55%,
surgery 20%
 MFI  400-m walk
 6-m walk
Cormie 201597 63 0 68 (17) Prostate On: ADT 100%, previous
radiotherapy 5%,
chemotherapy 2%
 CRP  FACIT-F  Timed STS
 Timed stair
climb
 6-m walk
Courneya 200499 a
Segal 2003102
155 0 68 (4) Prostate On: ADT 100%, previous
surgery + radiotherapy
 FACT-F
Courneya 200776 a
Courneya 200777
242 100 49 (15) Breast On: chemotherapy
100%previous surgery
 FACT-An
Courneya 2009105 120 42 53 (18) Lymphoma On: chemotherapy 44%  FACT-An
Courneya 201375 301 100 50 (9) Breast On: chemotherapy  TOI Fatigue
Daley 200778 108 100 51 (9) Breast Post: average 7.5 mth:
chemotherapy 74%,
radiotherapy 79%, hormone
therapy 73%, surgery 100%
 Revised PFS
Fairey 200530 a
Fairey 200560
52 100 59 (6) Breast Post: average 14 (SD 6) mth;
surgery 100%, radiotherapy
71%, chemotherapy 40%,
hormone therapy 46%
 IL: 1a, 4, 6, 10
 TNFa
Gomez 201179 16 100 49 (6) Breast Post: average 36 (SD 12) mth;
chemotherapy 100%, surgery
100%
 IL: 1a, 1b, 1Ra, 2,
2Ra, 3, 4, 6 to 10,
12, 13, 15 to 18
 TNFa
Headley 200481 32 100 51 (21) Breast On: chemotherapy 100%  FACIT-F
Hornsby 201461 a
Jones 201382
20 100 49 (43) Breast On: chemotherapy 100%  FACIT-F
Jones 201383 75 100 56 (9) Breast Post: no therapy 8%,
radiotherapy 63%,
chemotherapy 52%
 CRP
 IL6
 TNFa
Mock 200584 119 100 52 (9) Breast On: chemotherapy 42%,
radiotherapy 58%
 PFS  12-MWT
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Table 2 (Continued )
Study N Gender
(% F)
Age (y)
mean (SD)
Tumour stream Time period relative to
treatment and type(s) of
therapy
Outcome measure
Inﬂammation Fatigue Activity
Monga 2007101 21 0 69 (12) Prostate On: radiotherapy 100%  Revised PFS
Mustian 200985 a
Sprod 201090
38 71 60 (12) Prostate, breast On: radiotherapy 100%,
current hormone 8%, previous
chemotherapy 50%, surgery
84%
 BFI
 FACIT-F
 6-MWT
Mutrie 200762 203 100 52 (10) Breast On: surgery 100%,
chemotherapy only 8%,
radiotherapy only 28%,
combined 64%
 FACT-F  12-MWT
Naraphong 201586 23 100 47 (7) Breast On: chemotherapy 100%  Revised PFS
Oechsle 201465 48 29 52 (17) Acute myeloid leukaemia,
non-Hodgkin’s lymphoma,
germ cell tumour,
multiple myeloma
On: chemotherapy + HSCT
100%
 MFIS
Oldervoll 201169 231 62 62 (4) Gastrointestinal, breast,
lung, urological,
gynaecological,
haematological
On: chemotherapy 55%,
radiotherapy 6%, hormone
19%, targeted therapies 4%
 Fatigue
questionnaire
 Timed STS
 SWT
Payne 200887 20 100 65 (6) Breast On: hormone 100%  IL6  Revised PFS
Rief 201488 60 45 63 (29) Lung, breast, prostate,
melanoma, kidney, other
On: radiotherapy 100%,
hormone 43%,
immunotherapy 22%,
chemotherapy 75%
 EORTC
QLQ-FA13
Saarto 201289 500 100 52 (1) Breast Post: chemotherapy 100%,
radiotherapy 78%, endocrine
84%, hormone 84%
 FACIT-F  2-km walk
Segal 2009103 121 0 66 (7) Prostate On: radiotherapy 100%, ADT
61%
 FACT-F
Thorsen 200570 139 54 39 (1) Breast, gynaecological,
lymphoma, testicular
Post: average 28 d; surgery
82%, chemotherapy 100%,
radiotherapy 57%
 EORTC
QLQ-C30
Wang 201191 72 100 50 (10) Breast On: surgery 100%,
chemotherapy 100%,
radiation 44%
 FACIT-F  6-m walk
Wenzel 201392 126 39 60 (11) Breast, colorectal,
prostate, other solid
tumour c
On: radiotherapy 52%,
chemotherapy 35%, combined
7%, brachytherapy 6%
 PFS  12-MWT
Winters-Stone 201293 106 100 62 (1) Breast Post: chemotherapy 60%,
radiotherapy 88%
 SCFS  Timed STS
 4-m walk
Windsor 2004104 66 100 69 (1) Prostate On: radiotherapy 100%,
hormone 29%
 BFI  Modiﬁed
SWT
Wiskemann 201166 105 33 49 (15) Leukaemia, lymphoma
(various)
On: Allo-HSCT 100%  EORTC QLQ-C30
 MFI
 6-MWT
Yeo 2012106 102 44 67 (13) Pancreas On: surgery 100%,
chemotherapy /radiotherapy
73%
 FACIT-F
Yuen 200794 29 100 41 (13) Breast Post: 9 d to 35 mth; Surgery
100% chemotherapy 82%,
radiotherapy 77%
 PFS  6-MWT
ADT=Androgen deprivation therapy, AM-PAC SF=Activity Measure for Post-Acute Care Inpatient Mobility Short Form, AST=Androgen suppression therapy, BFI =Brief
Fatigue Inventory, CRP=C-reactive protein, EORTC QLQ=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (C30 or FA13 versions),
FACIT-F = Functional Assessment of Chronic Illness Therapy - Fatigue, FACT-F/An=Functional Assessment of Cancer Therapy-Fatigue/Anaemia, HSCT=Haematopoietic stem
cell transplantation, IL = interleukin, LASA=Linear Analogue Self Assessment, MFI =Multi-dimensional Fatigue Inventory, MWT=minute walk test, PFS =Piper Fatigue Scale,
SCFS=Schwartz Cancer Fatigue Scale, STS = sit to stand, SWT=Shuttle Walk Test, TNFa=Tumour Necrosis Factor-alpha, TOI =Trial Outcome Index.
a reports data on some or all of the same participants as the study below.
b n=3.
c n =8.
Research 73had adverse events. Of these, six participants withdrew from the
trials because of adverse event(s), including: dizziness, fatigue, bone
pain, chest pain, acute myocardial infarction, anaemia, dyspnoea
and knee pain. The adverse events that did not affect exercise
participation were back pain, lower limb pain, post-exercise
discomfort and a fall at home thatwas unrelated to the intervention.
A meta-analysis foundmoderate-quality evidence that exercise did
not increase the risk of an adverse event compared with usual care
and there was no difference between exercise modalities or
intensities (Table 4).Adherence was reported in 30 trials. Twenty-two
trials30,60,61,66,68,72,74,75,78–80,82,85,89–91,93–100,102–105 reported ad-
herence of > 75% attendance of exercise sessions or adherence
to the prescribed exercise protocol (in the case of non-supervised,
home-based exercise). Fifteen trials were supervised outpatient
sessions (14 centre-based,30,60,61,68,72,74,75,78–80,82,97,98,100,105 one
home-based),96 twowere a combination of home and centre-based
training89,93 and four were unsupervised interventions completed
at home.85,90,91,94,104 Twenty-two trials included strategies to help
improve exercise adherence and support behaviour change, such
Table 3
Summary of exercise interventions.
Study Program setting Exercise mode Session
duration
(min)
Frequency
(sessions/wk)
Program
duration (wk)
Intensity
Battaglini 200871 Supervised, centre-based,
individual
Combined aerobic,
resistance and ﬂexibility
21 to 32 2 15 40 to 60% VO2max
Baumann 201067 Supervised, inpatient
hospital-based
Combined aerobic and
ﬂexibility
10 to 20 10 Duration of
therapy
(mean 4, SD 2)
80% patient-achieved watt
load
Broderick 201368 a
Guinan 201380
Supervised, centre-based
group and individual
home
Aerobic 21 to 42 2 8 Poor 55 to 75% HRR
Fair 60 to 80% HRR
Average 65 to 85% HRR
(based on initial ﬁtness level)
Buffart 201495 a
Galvao 2010100
Supervised, centre-based,
group
Combined aerobic and
resistance
15 to 20
(aerobic)
2 12 Aerobic: 65 to 80% HRmax,
11 to 13 Borg RPE Resistance:
6 to 12 RM, 2 to 4 sets
Burnham 200272 Supervised, centre-based,
group
Aerobic 32 3 10 Low group: 40% HRR
Moderate group: 60% HRR by
week 10
Campbell 200573 Supervised, centre-based,
group
Combined aerobic and
resistance
10 to 20 2 12 60 to 75% age-adjusted
HRmax
Cantarero-
Villanueva 201374
Supervised, centre-based,
group
Combined aerobic and
resistance (aquatic)
40 3 8 Moderate RPE, 8 to 12 RM, 2 to
3 sets,
Chang 200863 Supervised, inpatient
hospital-based, individual
Aerobic 12 5 3 Target HR= resting HR + 30
Cheville 201396 Unsupervised, home-
based, individual b
Combined aerobic and
resistance
20
(aerobic)
4 8 Moderate RPE, 10 to 15 RM,
3.5 MET
Christensen 2014107 Supervised, hospital-
based outpatient,
individual
Resistance NR 3 9 10 to 12 RM, 4 sets
Coleman 201264 Unsupervised, home-
based, individual
Combined aerobic,
resistance and ﬂexibility
NR 3 15 Aerobic: 65 to 80% HRmax,
11 to 13 Borg RPE Resistance:
60 to 80% 1RM, 15 to 17 Borg
Cormie 201398 Supervised, centre-based,
group
Resistance 45 2 12 8 to 12 RM, 2 to 4 sets
Cormie 201597 Supervised, centre-based,
group
Combined aerobic and
resistance
45 2 12 Aerobic: 70 to 85% HRmax
Resistance: 6 to 12, 1 to 4 sets,
60 to 85% 1RM
Courneya 200499 a
Segal 2003102
Unsupervised, centre-
based, individual
Resistance NR 3 12 8 to 12, 2 sets, 60 to 70% 1RM
Courneya 200776 a
Courneya 200777
Supervised, centre-based,
group
Aerobic 15 to 45 3 Duration of
chemotherapy
(>12, median 17)
60 to 80% VO2max
Resistance NR 8 to 12, 2 sets, 60 to 70% 1RM
Courneya 2009105 Supervised, centre-based,
individual
Aerobic 40 to 45 3 12 60 to 75% VO2peak + 1 session/
wk interval at VO2peak from
wk 9
Courneya 201375 Supervised, centre-based,
individual
Standard aerobic 25 to 30 3 Mean 16 Aerobic: 55 to 60% VO2peak
Resistance: 10 to 12, 2 sets,
60 to 75% 1RM
High-dose aerobic 50 to 60
Combined resistance and
aerobic
50 to 60
Daley 200778 Supervised, centre-based,
individual
Aerobic 50 3 8 65 to 85% age-adjusted
HRmax, RPE 12 to 13
Fairey 200530 a
Fairey 200560
Supervised, centre-based,
group
Aerobic 15 to 35 3 15 70 to 75% VO2peak
Gomez 201179 Supervised, centre-based,
individual
Combined aerobic and
resistance
90 3 8 Aerobic: 70 to 80% HRmax
Resistance: 8 to 10 RM, 2 to
3 sets
Headley 200481 Unsupervised, home-
based individual
Aerobic 20 3 Duration of
therapy
NR
Hornsby 201461 a
Jones 201382
Supervised, centre-based,
individual
Aerobic 20 to 30 3 12 Initial: 60% baseline peak
Target: 2 sessions of 60 to 70%
and 1 interval session 100%
Jones 201383 Supervised, centre-based,
individual and
unsupervised, home-
based
Aerobic 30 3 (centre)
+ 2 (home)
26 50 to 80% HRmax
Mock 200584 Unsupervised, home-
based, individual
Aerobic 30 5 to 6 Duration of
therapy
(6 wk to 6 mth)
50 to 70% HRmax
Monga 2007101 Supervised, centre-based,
group
Aerobic 30 3 8 65% HRmax
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Table 3 (Continued )
Study Program setting Exercise mode Session
duration
(min)
Frequency
(sessions/wk)
Program
duration (wk)
Intensity
Mustian 200985 a
Sprod 201090
Unsupervised, home-
based, individual b
Combined aerobic and
resistance
NR 7 4 60 to 70% HRR, 3 to 5 RPE
Mutrie 200762 Supervised, group and
unsupervised, home-
based
Combined aerobic and
resistance
20 2 (group)
+ 1 (home)
12 50 to 75% HRmax
Naraphong 201586 Un-supervised, home-
based, individual b
Aerobic 20 to 30 3 to 5 12 40 to 60% HRmax, 12 to
14 Borg RPE
Oechsle 201465 Supervised, hospital-
based, inpatient
Combined aerobic and
resistance
40 5 median 2 40 to 60% 1RM
Oldervoll 201169 Supervised, centre-based,
group
Combined aerobic,
resistance, and ﬂexibility
30 2 8 NR
Payne 200887 Unsupervised, home-
based, individual
Aerobic 20 4 14 ‘Moderate’ walking activity
Rief 201488 Supervised, centre-based,
individual and
unsupervised, home-
based, individual
Resistance 30 3 24 NR
Saarto 201289 Supervised, centre-based,
group and unsupervised,
home-based, individual
Aerobic 45 to 50 1 (group) + 2
to 3 (home)
52 14 to 16 RPE, 86 to 92%
HRmax, 76 to 85% VO2max
Segal 2009103 Supervised, centre-based,
individual
Aerobic 45 3 24 70 to 75% VO2max
Resistance NR 8 to 12, 2 sets, 60 to 70% 1RM
Thorsen 200570 Supervised, home-based,
individual
Aerobic 30 2 14 60 to 70% HRmax, 13 to
15 Borg RPE
Wang 201191 Unsupervised, home-
based, individual
Aerobic 30 3 to 5 6 40 to 60% HRmax, 0.5 to
3 Borg RPE
Wenzel 201392 Unsupervised, home-
based, individual
Aerobic 20 to 30 5 Duration of
therapy (5 to 35)
50 to 70% HRmax
Winters-Stone 201293 Supervised, centre-based,
group and unsupervised,
home-based, individual
Resistance 60 3 52 8 to 10, 1 to 3 sets, 60 to 70%
1RM
Windsor 2004104 Unsupervised, home-
based, individual
Aerobic 30 3 4 60 to 70% HRmax
Wiskemann 201166 Partly supervised,
inpatient hospital-based,
individual and home-
based
Combined aerobic and
resistance
20 to 40
(aerobic)
3 (aerobic) + 2
(resistance)
1 to 4 pre-hospital
+ inpatient stay
+ 6 to 8 post-
hospital
Aerobic: 12 to 14 Borg RPE
Resistance: 8 to 20 RM, 2 to
3 sets, 14 to 16 Borg RPE
Yeo 2012106 Unsupervised, home-
based, individual
Aerobic 30 3 to 5 6 ‘Brisk walk’
Yuen 200794 Un-supervised, home-
based, individual
Aerobic 20 to 40 3 12 8 to 12 RM, 10 to 13 Borg RPE
Resistance NR
HRmax=maximum heart rate, HR=heart rate, HRR=heart rate reserve, MET=metabolic equivalents, NR=not reported, RM repetition maximum, RPE=Rating of Perceived
Exertion, VO2max =maximum volume of oxygen consumption, VO2peak = volume of oxygen consumption at peak exercise.
a Reports data on some or all of the same participants as the study below.
b With initial supervised instructional session.
Table 4
Meta-analysis of adverse events in exercise trials compared with usual care.
Outcome Subgroup
(modality or intensity)
Trials (n) Participants (n) Risk difference
(95% CI)
Quality of the evidence
(GRADE)
Adverse events Aerobic 1060,61,68,72,77,78,84,91,103,105 748 0.01 (–0.02 to 0.05) moderate a
Resistance 376,98,103 265 0.01 (–0.02 to 0.03) high
Combined 965,67,69,73,79,96–98,100 466 0.01 (–0.01 to 0.04) moderate b
Low-moderate intensity 865,72,74,75,84,91,96,98 495 0.01 (–0.01 to 0.04) high
Moderate-high intensity 1160,61,67,68,73,77–79,97,100,103,105 807 0.01 (–0.02 to 0.03) moderate a
Overall 21 1710 0.01 (–0.01 to 0.02) moderate a
GRADE=Grades of Research, Assessment, Development and Evaluation.
One trial72 was not included in the analysis due to no usual-care comparison.
GRADE working group grades of evidence (see reason for downgrade).
PEDro score < 6 was considered lower quality.
a Reason for downgrade: evidence of publication bias.
b Reason for downgrade: seven trials65,67,69,73,79,96,97 were rated lower quality.
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Figure 2. SMD (95% CI) of effect of exercise compared with usual care, on fatigue by
pooling data from 33 trials with subgroup analysis by tumour type (haematological,
mixed, solid), treatment phase (post-treatment, during treatment) and exercise
modality (aerobic, combined aerobic and resistance, resistance).
a Courneya et al.77.
Dennett et al: Dose-response of exercise for cancer survivors76as use of telephonemonitoring, exercise diaries, use of pedometers
and supervised ‘booster’ sessions.30,60,62,64,68,73,78,80,81,83–87,89–
92,94–98,100,103,104,106
Effects of exercise on health outcomes: meta-analysis
Fatigue
Meta-analysis provided moderate-quality evidence that exer-
cise had a positive effect on fatiguewhen comparedwith usual care
(SMD 0.32, 95% CI 0.13 to 0.52) (Figure 2, Table 5). When adjusting
for tumour type in subgroup analyses, there was insufﬁcient
evidence to suggest that exercise was effective for haematological
or mixed tumour types. There was strong evidence in favour of
exercise with respect to solid tumours and those undergoing
treatment (Table 6). With respect to mode of exercise, a
combination of aerobic and resistance training provided the
largest treatment effect, with smaller and similar estimated effects
for aerobic and resistance exercise alone (Table 6). Further meta-
analysis provided moderate-quality evidence that a reduction infatiguewasmaintained up to 6months after the interventionwhen
compared with usual care (Table 5). One trial was not included in
the meta-analysis because it did not have a usual-care control
group.75 This trial found no differences in fatigue when comparing
different exercise modalities and dose (with respect to duration).
Inﬂammation
A meta-analysis of ﬁve trials30,80,83,97,100 provided high-quality
evidence of a non-signiﬁcant reduction in levels of plasma CRP
following exercise when compared with usual care. A meta-
analysis of four trials79,83,90,107 provided moderate-quality evi-
dence that there was no signiﬁcant difference in plasma IL6 levels;
and meta-analysis of two trials79,107 provided moderate-quality
evidence that therewas no difference in IL8 or IL10 levels following
exercise (Table 5).
Two trials that were not included in the meta-analysis due to
insufﬁcient data did not show a signiﬁcant difference between IL6
levels87 or any of the cytokines tested.60 Another trial that was also
not included in the meta-analysis due to insufﬁcient data
demonstrated a signiﬁcant reduction in ILb and IL2 in the exercise
group during chemotherapy, and a signiﬁcant increase in IL8 levels
during the exercise intervention compared with usual care.82
Activity
Of the included trials, 18 reported on outcomes of functional
mobility and one reported on activities of daily living. A meta-
analysis of 15 trials provided very low-quality evidence of
improvement in walking endurance following exercise when
compared with usual care (Table 5, Figure 3). Sensitivity analysis
was completed because a single trial demonstrated a signiﬁcantly
larger effect than other trials. When this study was removed, there
was still a moderate effect in favour of the intervention, with high
levels of heterogeneity (61%), which was unable to be explained by
the study characteristics. There was evidence that exercise had a
signiﬁcant effect on walking endurance for solid tumour types
(Table 6). Moderate-quality evidence of four trials demonstrated
no difference in usual walking speed following exercise when
compared with usual care. There was also no difference in sit-to-
stand or stair climbing ability (Table 5). One trial found no
differences in patient-reported activities of daily living when
comparing combined exercise to usual care.96
Dose-response analysis: meta-regression
A total of 31 trials were included in a meta-regression analysis
of the dose-response effect of intensity and duration of exercise
programs on fatigue and walking endurance.
Meta-regression analysis demonstrated a signiﬁcant effect of
exercise intensity on fatigue. Aerobic exercise intensity was
negatively associated with treatment effect using linear regression
models. For every 1% increase in intensity (frommoderate to high)
there was an estimated reduction of SMD 0.029 (95% CI 0.001 to
0.056) in the positive effect of exercise on fatigue (Figure 4, top
panel, solid line). However, there was no evidence of this for the
aerobic exercise component of the combined exercise studies
(estimated reduction per 1% increase SMD 0.005 (95% CI –0.038 to
0.048) (Figure 4, top panel, dotted line). With respect to resistance
intensity (Figure 4, bottom panel) and exercise duration (Figure 5),
the meta-regression analyses did not detect any signiﬁcant
associations.
For walking endurance, only the intensity of aerobic exercise
was analysed using data from the aerobic and the aerobic
component of combined intervention trials. A quadratic meta-
regression model demonstrated that moderate-intensity aerobic
exercise (70% relative intensity) led to a peak effect (Figure 6). This
association was close to signiﬁcant. There was no association
detected for exercise duration (Figure 7).
Meta-regression analysis was not completed for markers of
inﬂammation because there were insufﬁcient data. All studies
measuring CRP and IL6 levels were moderate-intensity exercise.
Table 6
Meta-analysis, effect of exercise (post-intervention) on outcomes by subgroup.
Outcome Subgroup Trials (n) Participants (n) SMD (95% CI) I2 Quality of the evidence (GRADE)
Subgroup analysis by tumour stream
Fatigue Solid 2361,62,72–75,77,81,84–87,89,91–94,97,98,101–104,107 2168 0.37 (0.16 to 0.58) 82% moderate a
Haematological 463,64,66,105 360 –0.03 (–0.56 to 0.49) 82% low b
Mixed 467–70 446 0.17 (–0.34 to 0.68) 82% very low c
Endurance Solid 1062,73,84,85,91,94,95,97,98,104 650 0.92 (0.26 to 1.59) 93% very low d
Hematological 363,64,66 288 0.41 (–0.87 to 1.68) 93% very low e
Subgroup analysis by treatment phase
Fatigue Treatment 2661–64,66,67,69,73,75,77,81,84–86,91,92,95,97,101–105,107 1909 0.33 (0.12 to 0.53) 81% moderate a
Post-treatment 768,70,72,74,89,93,94,98 833 0.19 (–0.19 to 0.58) 81% moderate a
Subgroup analysis by exercise modality
Fatigue Aerobic 1861,63,68,70,72,75,77,81,84,87,89,91,92,94,101,103–105 1491 0.27 (0.00 to 0.54) 82% low f
Resistance 867,77,93,94,98,102,103,107 508 0.19 (–0.24 to 0.62) 82% moderate a
Combined 1162,64,66,67,69,73–75,85,94,95,97 975 0.41 (0.06 to 0.75) 82% low f
Endurance Aerobic 463,91,94,104 293 1.28 (0.36 to 2.20) 94% very low g
Resistance 297,101 29 0.18 (–1.36 to 1.72) 94% very low h
Combined 865,68,69,72,76,88,97,98,100 790 0.61 (–0.10 to 1.31) 94% moderate a
GRADE=Grades of Research, Assessment, Development and Evaluation.
GRADE working group grades of evidence (see reasons for downgrade).
PEDro score < 6 was considered lower quality.
a Reason for downgrade: heterogeneity.
b Reason for downgrade: three trials63,64,66 were rated lower quality, heterogeneity.
c Reason for downgrade: heterogeneity, all trials were rated lower quality, without blinded outcome measures and allocation concealment.
d Reason for downgrade: heterogeneity, ﬁve trials70,73,88,91,101 were rated lower quality, evidence of publication bias.
e Reason for downgrade: heterogeneity, all trials were rated lower quality, without blinded outcome measures and allocation concealment, wide conﬁdence intervals.
f Reason for downgrade: heterogeneity, evidence of publication bias.
g Reason for downgrade: heterogeneity, four trials were rated lower quality63,91,94,104, wide conﬁdence intervals.
h Reason for downgrade: heterogeneity, one trial was rated lower quality94, without blinded outcome measures and allocation concealment, wide conﬁdence intervals.
Table 5
Meta-analysis, overall effect of exercise on outcomes.
Outcome Trials (n) Participants (n) Time of
assessment
SMD (95%CI) I2 Quality of the
evidence (GRADE)
Inﬂammation
IL6 479,83,90,107 148 immed 0.15 (–0.79 to 1.08) 84% moderate a
IL8 279,107 43 immed –0.03 (–0.64 to 0.57) 0% moderate b
IL10 279,107 43 immed –0.31 (–0.92 to 0.30) 0% moderate b
CRP 530,80,83,97,100 264 immed –0.15 (–0.39 to 0.10) 0% high c
Fatigue d 3361–64,66–74,77,81,84–87,89,91–98,101–105,107 3336 immed 0.32 (0.13 to 0.52) 82% moderate a
762,68,74,77,85,104,107 721 2 to 6 mth post 0.39 (0.08 to 0.71) 71% moderate a
Activity
walking endurance e 1462–64,69,73,84,85,91,93,94,98,100,104 1032 immed 0.77 (0.26 to 1.28) 93% very low f
usual walking speed g 493,97,98,100 207 immed 0.22 (–0.32 to 0.77) 70% moderate a
sit to stand 569,74,93,97,100 479 immed 0.25 (–0.30 to 0.80) 87% moderate a
stair climb 297,100 120 immed –0.18 (–0.54 to 0.18) high
GRADE=Grades of Research, Assessment, Development and Evaluation, IL = interleukin, immed= immediate.
GRADE working group grades of evidence (see reasons for downgrade).
PEDro score < 6 was considered lower quality.
a Reason for downgrade: heterogeneity.
b Reason for downgrade: one trial79 was rated lesser quality.
c Reason for downgrade: ﬁve trials63,64,66,72,91 were rated lesser quality without blinded outcome measures and allocation concealment.
d Fatigue measures: Brief Fatigue Inventory, European Organisation for Research and Treatment of Cancer C30/FA13 Questionnaires, Functional Assessment of Chronic
Illness Therapy - Fatigue, Functional Assessment of Cancer Therapy - Fatigue/Anaemia, Fatigue Questionnaire, Linear Analogue Self Assessment, Multi-dimensional Fatigue
Inventory, Revised Piper Fatigue Scale, Trial Outcome Index - Fatigue.
e Walking endurance measures: 6-min and 12-min walk tests; 400-m and 2-km walk time; Shuttle Walk Test.
f Reason for downgrade: seven trials63,64,69,73,94,95,104werewithout blinded outcomemeasures and allocation concealment, evidence of publication bias and heterogeneity.
g Gait speed measures: 4-m and 6-m walk tests.
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This systematic review provided moderate-quality evidence
that exercise reduces fatigue in cancer survivors and very low-
quality evidence that exercise improves walking endurance in this
group. It also provided evidence of a negative dose-response
relationship of aerobic exercise intensity and fatigue, and of a peak
treatment effect of moderate-intensity aerobic exercise for
improving walking endurance. No signiﬁcant dose-response was
evident for the duration of weekly exercise. There was also
moderate-quality to high-quality evidence that there is no
signiﬁcant difference in inﬂammatory markers after completion
of an exercise program compared with usual care and no
signiﬁcant difference in usual walking-speed, sit-to-stand ability
or stair climbing ability.These ﬁndings support previous meta-analyses7,18,38–40 sug-
gesting that exercise can play a signiﬁcant role in reducing fatigue,
particularly in peoplewith solid tumours. Consistentwith previous
evidence, these effects may not be generalisable to haematological
cancers.38,40 Patients with haematological malignancies can
experience many complications during treatment, including
muscle atrophy, cachexia, anaemia, physical deconditioning and
psychological distress.64,108,109 In particular, anaemia has been
shown to affect people with haematological cancers more than
those with solid tumours110 and this is a known contributor to
cancer-related fatigue.27 Therefore, this complication may be less
able to be resolved through exercise.
Our review also demonstrated a signiﬁcant effect of exercise in
reducing fatigue in people undergoing treatment, but not after
treatment. A possible explanation could be a ceiling effect
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Figure 3. SMD (95% CI) of effect of exercise, compared with usual care, on walking
endurance by pooling data from 14 trials with subgroup analysis by tumour type
(haematological, solid) and exercise modality (aerobic, combined aerobic and
resistance, resistance).
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Previously, reductions in fatigue were not found to be maintained
after completion of the exercise program.19,40 However, in this
review, reduction in fatiguewasmaintained at follow-up. Thismay
[(Figure_4)TD$FIG]
Figure 4. Top panel:Meta-regression scatter plot of 25 trials showing the relationship bet
size, 95% CI), ﬁtted with linear regression lines: solid line – aerobic; dotted line – combin
between resistance exercise intensity (% of 1 repetition maximum) and the effect on fbe explained by a larger number of studies that included a speciﬁed
exercise dose, which is important because people need to exercise
with sufﬁcient duration and intensity to be able to induce long-
term physiological change to their health.
The signiﬁcant reductions in fatigue were accompanied by
signiﬁcant improvements in walking endurance. It has been
hypothesised that the physical dimension of fatigue has an organic
cause.111 Cancer survivors have low physical activity levels,112
which in turn reduce physical performance and impair skeletal
muscle function and cardiovascular ﬁtness. This cycle of decondi-
tioning, which perpetuates fatigue, can be broken through the
physical adaptations of exercise training. Exercise may also
provide the additional beneﬁts of improved mood and reduced
anxiety and fear, which are known contributors of cancer-related
fatigue.111,113,114
The safety of exercise in people with cancer was re-enforced by
this review, and evidenced by a low number of adverse events and
a non-signiﬁcant reduction in the inﬂammatorymarker CRP. There
was also no difference in the levels of the interleukins assessed.
These inﬂammatory markers have previously been linked to
tumour development and recurrence, as well as contributing to the
development of fatigue. The results in this review suggest that
exercise does not increase any pro-inﬂammatory markers, which
contribute to cancer risk and tumour development.
Moderate-intensity exercise has a greater effect on reducing
fatigue and increasing walking endurance than high-intensity
exercise. This is a plausible outcome, given the nature of the
mechanism of physiological changes as a result of exercise. Regular
exercise induces stress on the cardiovascular and muscular
systems in order for physical adaptation to occur.115 However,
in people with cancer, baseline exercise tolerance is reduced
secondary to the effects of disease and treatment-related factors.
Some tumours may directly disrupt pulmonary mechanics and
may also be accompanied by side effects such as weight loss,
anaemia and muscle wasting.116 Treatment such as chemotherapy
and radiotherapy can further exacerbate issues with oxygen
delivery by inducing pulmonary and cardiovascular damage as
well as increasing inﬂammation and reactive oxygen species; such
changes are correlated with change in myocardial strain.111,116
Therefore, while physical activity is important to relieve fatigue, a
balance in the amount of physical activity is also required.
However, it should be considered that other training factors such
as interval period, duration and length of the program mightween aerobic exercise intensity (% relative intensity) and the effect on fatigue (effect
ed. Bottom panel: Meta-regression scatter plot of 13 trials showing the relationship
atigue (effect size, 95% CI).
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Figure 6. Meta-regression scatter plot of 12 trials showing the relationship between aerobic exercise intensity (% relative intensity) and the effect on walking endurance
(effect size, 95% CI), ﬁtted with quadratic regression line.
[(Figure_5)TD$FIG]
Figure 5. Meta-regression scatter plot of 26 trials showing the relationship between exercise duration (minutes per week) and the effect on fatigue (effect size, 95% CI).
Research 79inﬂuence the effectiveness of high-intensity training, which this
reviewwas unable to assess. It should also be noted that therewere
no trials included in this review that assessed low-intensity
exercise. So, while there is evidence that moderate-intensity
exercisemay reduce fatigue and improvemobilitymore effectively
than high-intensity, it cannot be concluded that moderate-
intensity exercise is superior to low-intensity exercise for
improving these outcomes.
A dose-response relationship for exercise in relation to
inﬂammatory markers was unable to be established. Previous
literature has suggested that inﬂammatory biomarkers’ response
to exercise is dependent on the volume of mechanical work
completed.117 There were too few trials to establish a dose-
response relationship and a lack of variation in exercise intensity
levels in the trials that measured inﬂammation. There is evidencethat high-intensity or prolonged exercise duration can cause
immune suppression and increase susceptibility to infection in
healthy people.115 This is a major consideration, given that people
with cancer are often immunocompromised.
The current recommendations for exercise for people with
cancer are that they complete at least 150 minutes of moderate-
intensity exercise per week.6 It is also recommended that people
with cancer complete a combination of aerobic and resistance
exercise to achieve this goal. Results from this review support the
recommendation to complete moderate-intensity exercise, partic-
ularly in relation to aerobic exercise and the beneﬁts of combined
aerobic and resistance exercise programs for improving cancer-
related fatigue.19,38–40 The recommendation for the amount of
exercise required to achieve beneﬁts for fatigue and activity is less
clear. As such, cancer survivors should follow the recommendation
[(Figure_7)TD$FIG]
Figure 7.Meta-regression scatter plot of 11 trials showing the relationship between exercise duration (minutes per week) and the effect on walking endurance (effect size,
95% CI).
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exercise as tolerated.
It is believed that this was the ﬁrst review that analysed the
effect of dose on fatigue in cancer survivors using meta-regression
analysis across exercise modalities. It was also the ﬁrst to
investigate the effects of exercise on inﬂammatory biomarkers
in people with cancer using meta-analysis. It included only
randomised, controlled trials, which reduced the risk of selection
bias and increased conﬁdence in the results.
There were some limitations to this review. The search strategy
included only four databases and was restricted to the English
language, which posed some risk of publication bias. However,
relatively few articles were located through additional methods
and forest plots were analysed for publication bias. The results for
activity outcomes were based on trials where fatigue and/or
inﬂammation were also measured among the outcomes, so the
results for activity may not be based on a complete set of available
trials. However, previous reviews on exercise interventions for
adults with cancer have reported similar results in relation to
activity outcomes such as walking endurance.5,7 The overall
quality of the evidence was moderate to high, but there were high
levels of unexplained heterogeneity in the meta-analyses; this is
consistent with previous meta-analyses.5,19,38–40 This may have
limited the conﬁdence in the size of the pooled effect. To account
for this, subgroup and sensitivity analyses were completed based
on tumour stream and treatment phase. Therewas also evidence of
unequal variances between groups, which inﬂuence the way in
which the differences of means should be standardised; Glass’ D
effect size was used to overcome this. The analyses were also
conducted using Cohen’s d and the main ﬁndings remained intact.
Combining a number of relative-intensitymeasures (eg, maximum
heart rate, VO2max and Borg) may also be a limitation. However,
since these are effective measures of intensity and standardised
effects were used, this was unlikely to be an issue.
In conclusion, this review of 42 randomised, controlled trials
supports the growing body of evidence that exercise is a safe and
effective intervention for reducing fatigue and improving mobility
in adult cancer survivors. It was also able to establish a dose-
response relationship of intensity for aerobic exercise, supporting
current recommendations emphasising moderate-intensity aero-
bic training in exercise programs for cancer survivors. Theseﬁndings demonstrated greatest effect in people with solid
tumours, with no signiﬁcant effect evident for people with
haematological malignancies.What is already known on this topic: For people with
cancer, exercise has beneficial effects on strength, cardiovas-
cular function, fatigue and quality of life. However, the ideal
mode and intensity of exercise for people with cancer is
unclear.
What this study adds: Exercise is safe and reduces fatigue
and increases endurance in cancer survivors. Moderate-inten-
sity exercise appears to be the most appropriate aerobic
exercise for benefits on fatigue and walking endurance.eAddenda: Appendix 1 can be can be found online at doi:10.
1016/j.jphys.2016.02.012
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